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Circulating tumor cells (CTCs) have garnered a lot of attention in the past few decades. 
Isolation of these rare cells from the billions of blood cells has been a challenge until 
recent times. With the advent of new sensitive technologies that permit live cell isolation 
and downstream genomic analysis, the existing paradigm of CTC research has evolved 
to explore clinical utility of these cells. CTCs have been identified as prognostic and phar-
macodynamic biomarkers in many solid tumors, including lung cancer. As a means of 
liquid biopsy, CTCs could play a major role in the development of personalized medicine 
and targeted therapies. This review discusses the state of various isolation strategies, 
cell separation techniques and key studies that illustrate the application of liquid biopsy 
to lung cancer.
Keywords: circulating tumor cells, liquid biopsy, review of literature, prognostic biomarkers, non-small-cell lung 
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introduction
Lung cancer is the leading cause of cancer worldwide, accounting for 160,000 deaths in the United 
States in 2014 (1) with a 5-year survival rate of 20% (2). Approximately 224,000 new cases of lung 
cancer were reported in 2014 (2). Smoking is the leading risk factor (3). Non-small-cell lung cancer 
(NSCLC) constitutes 80% of all new lung cancer cases (4). Over 50% of patients are diagnosed 
initially with locally advanced or metastatic disease with worse outcomes. Survival is improved 
through screening, early diagnosis, and treatment (5). However, currently approved screening strat-
egies involving low-dose CT scans have a low sensitivity and high false positive rates of >90% (5). 
There is an unmet need for additional biomarkers that can improve the sensitivity of low-dose CT 
screening, particularly in patients with indeterminate pulmonary nodules. Following a diagnosis of 
lung cancer and stage-specific therapy, currently, the only available techniques to monitor disease 
progression other than clinical symptoms are periodic CT scans done every 3–6 months. Earlier 
detection of recurrence in cases of earlier stages of lung cancer (stages I and II) is needed to direct 
certain subsets of patients for treatment of oligometastatic disease; this may include surgery and/
or radiation therapy. In cases of patients with more advanced lung cancers, surveillance CT scans 
may demonstrate progression of disease; repeat biopsies of these recurrent/progressive lesions 
allow us to determine the underlying resistance mechanisms, in cases of lung cancers associated 
with specific molecular targets (6). This type of surveillance may miss early recurrence/resistance 
and identification of treatable oligometastatic disease. In addition, repeat biopsies are invasive 
and not without risk. There is an unmet need for earlier detection of resistance in this subgroup 
FiGURe 1 | Liquid biopsy of lung cancer: different applications of using CTCs as surrogate biomarkers in lung cancer.
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of patients using a minimally invasive approach, which could 
potentially serve as decision aid for subsequent alternative 
therapies targeting secondary mutations or alternative pathway 
activation (7, 8). Furthermore, a better non-invasive approach 
for serial monitoring is necessary to address other clinical and 
research unmet needs, not only for early response assessment 
for targeted therapies but also for novel immunotherapies 
where radiologic response may lag behind or be erroneous (e.g., 
pseudo-progression).
Emerging research in blood-based biomarkers provide new 
opportunities to diagnose lung cancer earlier and also to assist 
with detection of earlier recurrence. These biomarkers include 
circulating tumor cells (CTCs) (9) and circulating cell-free 
nucleic acids (CfNA) (10–12). CfNA are released from apop-
totic or necrotic tumor cells (13). Besides plasma, tumor nucleic 
acids have also been detected in other fractions of blood, such 
as platelets (14), extracellular vesicle exosomes (15), and buffy 
coat (leukocyte-enriched) (16). New technologies are being 
developed to increase the sensitivity and specificity of cfNA 
detection in the blood (17). CTCs, on the other hand, have 
been extensively studied as prognostic and pharmacodynamic 
biomarkers in many cancers (18–22). Both cfNA and CTCs 
were demonstrated to correlate with tumor burden and revealed 
genetic signatures of primary and metastatic tumors (23, 24). 
CTC processing technologies, however, have unique advantages 
over cfNA, by permitting a vast array of molecular and functional 
studies, including cell culture, xenograft implantation, and ex 
vivo drug testing (Figure  1) (25). CTCs represent a subset of 
tumor cells that have acquired the ability to disseminate from 
the primary tumor and intravasate to the circulatory system 
(26). Sampling CTCs may be a viable non-invasive alternative to 
tissue biopsies for diagnosis of lung cancers. In many patients, 
however, CTCs are quite low in number, and need to be isolated 
from an overwhelming majority of blood cells (1 CTC: 1 bil-
lion blood cells). We have reported capability of detecting and 
characterizing CTCs from early stages of lung cancer (27). CTCs 
have demonstrated utility in surveillance of patients and their 
changing numbers predict progression-free survival (PFS) and 
overall survival (OS) in several cancers (19, 28). Additionally, 
CTCs have been proposed as surrogate biomarkers in a multi-
tude of research areas, including the selection of neoadjuvant 
and adjuvant therapy, detection of recurrent disease, and as 
pharmacodynamic biomarkers of novel therapeutics (22, 26, 
29–34). In this review, we summarize current technological and 
scientific advancements in CTC research specifically pertaining 
to lung cancer and discuss possible future directions (Figure 2).
CTC isolation Technologies
Circulating tumor cells have now been proposed as surrogate 
biomarkers in over 270 clinical trials (10). However, to date, CTCs 
have not been incorporated into routine clinical practice for man-
agement of patients with cancer. The efforts to identify biological 
relevance and clinical utility of CTCs parallel the development 
of CTC isolation technologies. There are several key parameters 
worthy of consideration when designing a method to isolate 
CTCs: (a) specificity, (b) sensitivity, (c) purity, (d) viability, and 
(e) throughput. All the downstream assays, such as molecular and 
genomic analysis and culturing for ex vivo drug testing, depend 
on these factors. We will discuss about pros and cons associated 
with current isolation technologies in general and specifically as 
they pertain to lung cancer (Table 1).
FiGURe 2 | Application of CTCs in lung cancer: (A) less than 5 CTCs/7.5 ml of blood predicted improved survival by CellSearch system (19).  
(B,C) Higher numbers of CTCs were detected in metastatic lung cancer than cancer without distant metastasis (35). (D) NSCLC CTCs were detected by ISET 
technology and stained positive for EGFR (36). (e) NSCLC CTCs were isolated by CellSearch system and stained positive for EGFR and CK (33). (F) Morphologic 
features of CTCs from different histologies of NSCLC (37). (G) CTCs were detected by HD-CTC assay and stained positive for CK (red) and negative to CD45 (green) 
(38). (H,i) Mutations were detected in CTCs, primary tumors, and metastatic sites. Copy number variation patterns among single CTCs, primary tumor, and metastatic 
sites (39). (J) ALK rearrangement patterns in CTCs and primary tumor (40). (K,L) ALK rearranged CTCs stained positive for vimentin (K) and N-Cadherin (L) (40).  
(M) ROS1-rearranged CTCs were compared to primary tumor (41). (N) CTCs isolated from SCLC patients generated tumor in a mouse (42). (O) CTC-derived xenografts 
were stained for different protein markers (42). (P) NSCLC CTCs were isolated and expanded by a microfluidic co-culture model and stained positive for CK (27).
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Collectively, there are two major approaches; one is anti-
epithelial cell adhesion molecule (EpCAM) dependent while the 
other is EpCAM independent. The FDA approved CellSearch 
technology utilizes EpCAM-coated magnetic beads to isolate 
CTCs in a multitude of cancers in spite of limited detection 
efficiency (32% in lung cancer) (19, 43–45). Microfluidic-based 
technologies have changed the existing paradigm for recovery of 
CTCs. Microfluidic chips coated with EpCAM and microfluidic 
systems utilizing immunomagnetic principles have been shown 
to capture CTCs from lung cancer samples with 100% efficiency 
(46–49). These antibody-based microfluidic devices have the 
advantage of high sensitivity, low numbers of white blood cells 
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contamination (can be as low as 1,500 WBCs), as well as preserv-
ing the viability of CTCs due to minimal handling of whole blood. 
The drawback is that they suffer from limited throughput due 
to low flow rates (1–3  ml/h) and a requirement for antibody–
antigen interaction. Another problem with EpCAM-dependent 
methods is that they can only capture a subset of CTCs and miss 
cells undergoing epithelial–mesenchymal transition (EMT) (10). 
Wit et  al. recovered lung CTCs by filtration from the waste of 
CellSearch system (50). The percentage of patients having more 
than 5 cells per 7.5  ml of blood increased from 15% (EpCAM 
positive) to 41% (EpCAM positive and negative). This suggested 
that including the EpCAM negative population increased CTC 
recovery.
By contrast, the label-free approaches to isolate CTCs do not 
rely on the expression of specific cell surface markers but instead 
on inherent CTC properties such as size, deformability, or dielec-
tric susceptibility, and/or negative selection of WBCs (51–60). 
While improvements in size-based and other physical separation 
techniques have allowed higher throughput over the years, they 
suffer from limitations related to heterogeneity of tumor cells, 
contamination with blood cells and result in lower yield and 
specificity compared with the antigen-based systems (61). For 
example, CTCs within a patient may have a wide range of sizes 
(>4–30 μm) and many of them may overlap in size with blood 
cells (62). More recently, several new integrated platforms have 
emerged for CTC isolation. Liu et  al. introduced an integrated 
device that separates blood cells and CTCs by deterministic lateral 
displacement, followed by an affinity-based enrichment (9.6 ml/h) 
(63). The CTC-iChip by Ozkumur et al. combines magnetic labe-
ling and high throughput sorting of cells (8  ml/h) (64), which 
is based on the principle of conjugating capturing antibodies on 
magnetic particles and enriching rare cells by applying external 
magnetic forces (65). While EpCAM-independent systems allow 
high throughput and an unbiased surface marker-independent 
approach that can capture cells undergoing EMT (66), the need 
for multiplexing and pre-processing of blood samples make it 
cumbersome and time consuming. Chang et al. employed similar 
principles by labeling CTCs with antibody cocktail conjugated 
with magnetic beads followed by size-based filtration to trap 
CTCs on chip for immunofluorescence staining (67). This system 
also operates at high flow rates (2 ml/min) but requires RBC lysis 
and the average WBCs contamination was around 4000.
Other label-free technologies that are not microfluidic based 
are also employed in clinical evaluation of lung CTCs. The isola-
tion by size of epithelial tumor cells (ISET) technology, isolating 
CTCs based on their larger size, is among the earliest developed 
EpCAM-independent approaches which filter CTCs from blood 
cells as they pass through a membrane filter (68). CTCs were 
detected in 80% of samples from stages IIIA–IV NSCLC patients 
using ISET compared with 23% using CellSearch (36). Using the 
same approach, CTCs were present in 65% of NSCLC patients in 
a more recent report (69). In another study, an automatic micro-
scope scanning and analysis technology called high-definition 
CTC (HD-CTC) assay was utilized to examine CTCs from 
stages I–IV NSCLC patients (38, 70). This technology permits 
high-resolution imaging of CTCs and is not biased toward size 
or surface markers. Recently, DNA aptamers were utilized to 
isolate CTCs from NSCLC patients (71). CTCs were identified in 
86% of the samples that were positive for aptamers and pan-CK. 
The ISET, HD-CTC assay, and aptamer approach require RBC 
lysis and have limited purity of isolated CTCs, therefore posing 
constraints on molecular and functional studies of the cells.
TABLe 1 | Comparison of CTC isolation technologies.
Technology Approach Flow 
rate 
(ml/h)
Recovery 
cell lines 
Purity 
wBCs 
(ml)
Patient samples whole blood Genomic 
analysis
Live 
cells
Culture Drug 
testing
CellSearch EpCAM-coated magnetic 
beads
NA >80% Low <50% in breast (43) N N N N N
32% in lung cancer, 
5CTCs/7.5ml (19)
Epic Sciences No enrichment, RBCs lysed 
blood deposited on slides
NA NA None 73% in lung cancer (38), 
55% in melanoma (112)
N Y, single cell 
for copy 
number 
N N N
Mag Sweeper Flow through immunomagnetic 
capture
62 ± 7% 100% in metastatic 
breast cancer, 
12CEpCs/9 ml (113)
Y, need 
dilution 
Y Y N NA
ISET Size-based filtration NA One CTC 
per 1 ml of 
blood
NA 80% in lung cancer  
(36, 40, 68)
N Y, FISH N N N
CTC iChip Size-based separation +ve or 
−ve selection with mag beads
9.6 >95% for 
−ve
>10,000 
for −ve
90% from multiple types 
of metastatic cancers, 
including lung cancer (64)
Y, not a 
single step
Y, single-
cell RNA 
expression
Y Y Y
78–98% for 
+ve
<10,000 
for +ve
FACS Sorting Surface marker-based 
selection 
Very 
low
NA Very Low <10% (99) Y Y Y Y N
RosetteSep kit Depletion of WBCs NA NA NA NA (42, 101, 109) Multiple steps Y Y Y NA
CTC chip Positive selection 1 >95% NA 72% in lung cancer (27) Y Y Y Y N
GO Chip Nanopillars with graphene 
oxide
1–3 >95% <1,000 >95% sensitivity, 10 
CTCs/ml (46)
Y Y Y Y N
2–5 CTCs
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In summary, CTC technologies have evolved rapidly in the 
last decade, yet there is none that has FDA approval other than 
CellSearch. However, to incorporate CTCs into basic as well as 
small cohort clinical research, there are more tools than ever before, 
with microfluidic devices leading the way with higher sensitivity. 
Any ideal CTC technology should offer high throughput, minimal 
handling (whole blood) that can separate live CTCs with high sen-
sitivity and specificity. Presently, there is no single technology that 
is optimal for every downstream analysis; the choice of technology 
is driven more by the end user application and ease of accessibility 
to the technology. Immunoaffinity-based technologies offer both 
sensitivity and specificity albeit with dependence on the known 
biomarker. A high throughput system that requires minimal 
pre-manipulation of whole blood and that can operate with either 
positive selection or negative depletion approach seems to be 
most promising for lung cancer CTC isolation. Furthermore, the 
efficiency of positive selection depends on the discovery of lung 
cancer-specific surface markers such that a cocktail of capturing 
antibodies can be applied to target a broader range of lung CTCs.
CTCs as Prognostic and Predictive 
Markers in Lung Cancer
Previously, the oncology community believed that there was little 
merit in diagnosing recurrence or progression earlier in patients 
who had surgery for earlier stages of lung cancer or following 
initial therapy for locally advanced/metastatic NSCLC. This was 
related to poor therapy choices at recurrence/progression that 
often does not alter clinically significant outcomes such as PFS 
and OS. There has been a rethink of this approach in a small, 
but significant minority of patients. This relates to the emerging 
field of therapy directed at oligometastatic disease such as local 
radiation or use of immunotherapy or newer biologics that may 
render patient disease free for a significant amount of time, even 
if OS is not affected. Many of these therapies are also better toler-
ated with broader therapeutic windows. We will, in this section, 
outline various studies relating CTCs to prognosis in lung cancer 
as well as studies that predict therapy response.
Hofman et al. used ISET technology to isolate CTCs from 208 
NSCLC patients with stages I–IV cancer. Fifty percent of these 
patients had CTCs by morphological examination (37). A cut-off 
value of >50 corresponded to shorter PFS and OS. There was, 
however, no direct correlation between numbers of CTCs and 
disease stage, or other clinicopathologic parameters. Therefore, 
CTCs and tumor staging appeared to be independent prognostic 
factors. In another study using the CellSearch system, there were 
greater numbers of CTCs in metastatic lung cancer patients 
(P  <  0.001) compared to patients without distant metastases 
(35). Similarly, another study using the CellSearch system found 
that in 101 patients with stage III/IV NSCLC, numbers of CTCs 
were higher in stage IV compared to stage III patients (19). With 
a threshold of 5 CTCs in 7.5 ml blood, patients were categorized 
into favorable and unfavorable groups. Both the PFS (6.8 vs. 
2.4  months) and OS (8.1 vs. 4.3  months) were higher in the 
favorable group than the unfavorable (P < 0.001). Additionally, 
CTC numbers decreased with one cycle of chemotherapy. 
Reduction in numbers of CTCs with therapy correlated with 
improved PFS (6.9 vs. 2.4  months; P =  0.005) and OS (8.8 vs. 
3.9 months; P < 0.001). This study highlighted that CTC numbers 
were not only prognostic, but also that a change in CTC number 
with therapy predicted disease progression dynamically.
Dorsey et  al. investigated the change of CTC number in 
patients with localized NSCLC undergoing radiation treatment. 
Using a telomerase-based detection assay, 65% of the patients 
were positive for CTCs prior to treatment. CTC numbers signifi-
cantly reduced after radiation (9.1 vs. 0.6 CTCs/ml; P < 0.001). 
This study suggested that analyzing CTC can serve as “real-time 
liquid biopsies” accompanying treatment to monitor tumor 
progression (72). Several studies examining CTCs in advanced 
NSCLC patients receiving chemotherapy have shown that 
>2 CTCs/7.5 ml or any increase in CTC numbers after therapy 
predicted lower OS and PFS (P = 0.05) (33, 34, 73). To improve 
detection sensitivity, CTCs from pulmonary vein blood were 
examined in patients undergoing surgery (74–76). Compared 
to peripheral blood CTCs (2 out of 30 positives), pulmonary 
CTCs were present in 22 out of 30 samples before surgery 
(0–1122 cells/2.5 ml, median, 4 cells/2.5 ml) (75). Surprisingly, 
the number of pulmonary CTCs increased significantly after sur-
gical manipulation (0–1855 cells/2.5 ml, median, 60 cells/2.5 ml); 
this increase also correlated with pathological evidence of 
microscopic lymphatic invasion (P =  0.043). Chudasama et  al. 
investigated the effect of endobronchial cryotherapy (EC) on 
shedding of CTCs before and after the procedure in peripheral 
blood (77). CTC count increased following cryotherapy in 15 out 
of 20 advanced stage patients (P = 0.0086) which predicted poor 
prognosis during follow-up. In summary, these studies suggest 
that monitoring change of CTC numbers during therapy is 
prognostic for NSCLC. An increase of CTC counts may entail 
additional follow-up examinations.
More recently, several groups have reported on the prognostic 
value of CTC clusters called circulating tumor microemboli (CTM) 
(36, 70). Krebs et  al. observed the prevalence of CTM by ISET 
technology in 43% of patients with stage IIIB/IV NSCLC (36). In 
another study using HD-CTC assay, 50% of NSCLC patients with 
stages I–IV disease had CTM (70). It was shown that CTM can 
be used to diagnose lung cancer when combined with clinical and 
imaging data. The existence of CTMs was also observed in pulmo-
nary venous (PV) blood of patients with NSCLC (76). Among 130 
patients tested, 74% of them were positive for CTCs. CTMs were 
detected in 33% of samples which predicted tumor recurrence and 
worse disease-free survival rate (P < 0.01).
Other studies correlated prognosis to the presence/absence of 
protein expression of CTCs in NSCLC. As demonstrated by Wu 
et al., CTCs in multiple types of cancer, including lung cancer, 
harbored a mixed population of epithelial and mesenchymal 
phenotypes (78). Nel et al. stained CTCs for both epithelial mark-
ers such as EpCAM and pan-cytokeratin (CK) as well as mesen-
chymal markers such as N-cadherin and CD133 (79). Different 
subsets of CTC populations were identified with heterogeneous 
combinations of epithelial and mesenchymal characteristics. 
CD133 expression correlated positively with N-cadherin. The 
presence of these mesenchymal markers predicted shorter PFS 
(2 vs. 8 months, P = 0.003) likely due to emergence of chemore-
sistant populations.
TABLe 2 | CTCs as prognostic markers in lung cancer.
Study Technology Sensitivity (% of patients 
positive for CTCs)
Prognostic significance
Hofman et al. (37) ISET 50% >50 CTCs corresponded with shorter OS and PFS
208 NSCLC patients (stages I–IV)
Tanaka et al. (35) CellSearch 30% in all patients
71% in metastatic patients
CTC count was higher in lung cancer than non-malignant 
patients. CTC count was higher in patient with distant 
metastasis
125 lung cancer patients (stages I–IV)
25 patients with non-malignant diseases
Kreb et al. (19) CellSearch 21% at baseline (32% at 
stage IV, 7% at stage IIIB)
>5 CTCs/7.5 ml blood predicted shorter PFS and OS. 
A reduction in CTC count after chemotherapy predicted 
improved survival
101 NSCLC patients (Stages III–IV)
Dorsey et al. (72) Telomerase-based assay 65% before RT CTC count decreased in patients responding to RT
30 NSCLC patients received radiation therapy
Juan et al. (73) CellSearch 24% at baseline No significant prognostic conclusion was made
37 NSCLC patients [Advanced stage (IIIB–IV)]
Muinelo-Romay et al. (34) CellSearch 42% at baseline >5 CTCs/7.5 ml blood at baseline predicted shorter 
PFS and OS. CTC count increase during chemotherapy 
correlated with worse PFS and OS
43 NSCLC patients (stages IIIB and IV)
Punnoose et al. (33) CellSearch 76% at baseline Reduction in CTC count after chemotherapy predicted 
longer PFS41 NSCLC patients (Advanced stage)
Sienel et al. (74) Ficoll-Hypaque 
Centrifugation
18% in pulmonary venous 
(PV) blood
Presence of CTCs in PV blood was associated with 
shorter survival especially in patients with lymph node 
involvement
62 NSCLC patients (stages I–III)
Hashimoto et al. (75) CellSearch 73% in PV blood before 
surgery
CTC count in PV blood significantly increased after 
surgery, which predicted lymphatic tumor invasion30 NSCLC patients (stages I–IV)
Funaki et al. (76) RosetteSep kit 74% in PV blood after tumor 
resection
The presence of CTM in PV blood predicted worse PFS
130 NSCLC patients (stages I–IV) Circulating tumor 
microemboli (CTM) in 33%
Chudasama et al.(77) ScreenCell 25% at baseline, 75% after 
endobronchial cryotherapy (EC)
CTC count increased after EC
20 NSCLC patients (stages III–IV)
Carlsson et al. (70) HD-CTC assay 50% positive to CTM CTM along with clinical and imaging data can serve as 
predictor of malignant vs benign diseases104 NSCLC patients (stages I–IV)
25 patients with benign diseases
Pirozzi et al. (114) Ficoll-Hypaque 
Centrifugation
24% in PV blood No association found between presence of CTCs and 
prognosis45 NSCLC patients (stages I–III)
Nel et al. (79) Ficoll-Paque CD45 
magnetic depletion
100% Presence of mesenchymal markers CD133 and 
N-cadherin in CTCs predicated shorter PFS43 NSCLC patients (stages IIB–IV)
Hou et al. (81) CellSearch and ISET CTCs in 85% More than 50 CTCs/7.5 ml blood predicated shorter OS
97 SCLC patients CTM in 32%
Huang et al. (82) CellSearch Not reported CTC count decreased after chemotherapy
26 SCLC patients Median CTC count at 
baseline is 75 (0–3430)
CTC count at baseline and change of CTC numbers after 
treatment not associated with survival
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Small-cell lung cancer (SCLC) accounts for 13% of newly 
diagnosed lung cancer and is considered aggressive with early dis-
semination and poor prognosis (80). Hou et al. demonstrated that 
CTCs were present in 85% of SCLC compared to 21% in NSCLC 
patients (19, 81). Higher CTC numbers were noted in SCLC than 
NSCLC; >50 CTCs/7.5 ml of blood predicted shorter PFS (4.6 
vs. 8.8 months; 95% CI) and OS (5.4 vs. 11.5 months; 95% CI). 
A reduction in CTC number after chemotherapy was associated 
with longer PFS (9.6 vs. 4.1 months; 95% CI) and OS (10.4 vs. 
4.1 months; 95% CI). Huang et al. evaluated prognostic signifi-
cance of CTCs in SCLC. CTCs were enumerated before and after 
chemotherapy (82). A reduction of CTCs was observed in 16/26 
patients after treatment. However, CTC count at baseline and the 
percentage change of CTCs were not statistically significantly 
associated with survival. A summary of the studies investigating 
the prognostic value of CTCs in lung cancer is shown in Table 2.
Taken together, several studies have demonstrated the prognos-
tic utility of CTCs in lung cancer. CTC count and change of CTC 
number after surgery, radiation, and chemotherapy may serve as 
predictors of recurrence. At the current time, however, CTCs are 
not routinely used as prognostic or predictive markers in clinics. 
There are several reasons for this. Most of the previous studies used 
CellSearch or traditional approaches without pre-enrichment, 
which limited sensitivity of the tests in detecting CTCs. Many 
of the studies had small sample sizes (<100) limiting statistical 
significance. This resulted in contradictory or inconclusive find-
ings. Given newer and extremely sensitive technologies that allow 
isolation and accurate characterization of CTCs, large numbers of 
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patients within specific stages of lung cancer need to be enrolled. 
The stringent biomarker studies need to use training and test sets 
that will allow independent validation and reproducibility.
Applications of CTCs in the era of 
Targeted Therapies in Lung Cancer
The past two decades have seen a large discovery effort such that 
lung cancer is not considered one homogeneous cancer. Over 
64% of all lung cancers have an underlying driver mutation that 
is responsible for proliferation of the cancer and many of these 
mutations are mutually exclusive (83). Nearly 30% cases of these 
driver mutant lung cancers have an approved therapy (targeted 
therapy). The most common ones are adenocarcinomas (AC) 
that  are associated with mutations in the EGFR gene or rear-
rangements in the ALK and ROS-1 gene (84). Additional genomic 
aberrations include those in BRAF, AKT1, ERRB2, PIK3CA, and 
fusions in RET (85). Detection of mutation by biopsy may not fully 
reflect intratumoral heterogeneity (86). In this regard, sampling 
CTCs as “liquid biopsy” may complement solid biopsy to inform 
effective targeted therapies. Liquid biopsy is also non-invasive 
allowing dynamic monitoring of disease progression (13).
One of the earliest investigations was identifying EGFR muta-
tions in CTCs from metastatic NSCLC known to harbor these 
mutations. In 11 out of 12 patients, expected mutations were 
validated, including the appearance of the resistance mutation 
T790M. In this study, CTC numbers paralleled radiographic 
response and offered first insights into genomic profiling of CTCs 
as a way to monitor genotypic changes during therapy (24). Two 
recent studies examined EGFR mutation in advanced NSCLC 
patients. Marchetti et al. demonstrated that EGFR mutation was 
detected in CTCs of 84% of the patients carrying EGFR-mutant 
primary tumors (87). In 94% of the cases, mutations found in 
CTCs matched the mutations in tumor tissues. The unmatched 
mutations in CTCs and primary tumors were likely due to tumor 
heterogeneity between primary lesions and metastatic sites. 
Breitenbuecher et al. utilized a RT-PCR assay to detect in-frame 
deletions in the EGFR exon 19 (88). All eight EGFR-mutant 
patients demonstrated identical mutations in the CTCs. EGFR 
mutations were also detected from circulating DNA of advanced 
lung AC patients with 73% sensitivity (89). Both CTCs and cfDNA 
can be used in future research to determine the “best in class” 
EGFR tyrosine kinase inhibitors (TKI) for individual patients.
Other studies focused on investigating ALK rearrangement 
in CTCs (40, 90). By performing filter-adapted fluorescent 
in  situ hybridization (FA-FISH), researchers identified unique 
ALK-rearranged pattern in CTCs with a mesenchymal pheno-
type. This unique population of CTCs may be highly invasive, 
behaving as metastasis initiation cells (91). Adapting the similar 
approach, ROS1 rearrangement was investigated in NSCLC CTCs 
and compared to tumor biopsy specimens (41). Among four 
patients tested, CTCs harbored similar split patterns as tumors 
but exhibited an increase in ROS1 copy number. The number of 
ROS1-rearranged CTCs increased in one patient who did not 
respond to crizotinib treatment. In another study, whole-genome 
amplification of single CTCs from lung cancer patients was 
performed followed by analyzing copy number variation (CNV) 
in addition to somatic mutations (39). It was demonstrated that 
CTCs obtained from the same patient exhibited similar CNV pat-
tern but was distinguishable from CTCs obtained from a different 
histology of lung cancer. These studies suggest that profiling CTC 
genome can predict cancer progression as well as emergence of 
secondary resistant mechanisms to be further targeted by therapy.
CTCs as Biomarkers for early Diagnosis  
of Lung Cancer
Sensitive detection of CTCs provides opportunities for early 
diagnosis of lung cancer. CTCs can be shed by primary tumor 
even at early stages of tumor development (92, 93). It was 
demonstrated that the presence of CTCs in 5 out of 168 chronic 
obstructive pulmonary disease patients predicted occurrence of 
lung nodules 1–4 years after initial detection of CTCs (94). In 
one study, CTCs were isolated from 84% of lung cancer patients 
of various stages, including early stage of lung cancer (57.1%) 
(95). CTCs were identified with CD45-FISH method that was 
reported to increase detection sensitivity by including cells defi-
cient in epithelial markers like CK. Two studies utilized tumor-
specific ligand folate and an oligonucleotide followed by qPCR 
and immunofluorescence staining to identify NSCLC CTCs (96, 
97). CTCs were observed in more than 70% of all stages with 
67.2% in stage I cancer. It was further demonstrated that CTCs 
can be more sensitive for early diagnosis of lung cancer than 
blood serum markers such as cyfra21-1 or CEA. More recently, 
one study evaluated CTCs from potential lung cancer patients 
to predict malignancy of the lung lesions as a way to circum-
vent sampling bias by solid biopsy (98). CTCs isolated shared 
similar morphological features and histology (72%) with biopsy 
specimens. In stage I patients tested (42%), the numbers of CTCs 
correlated with tumor size (P = 0.001). Our group also demon-
strated that CTCs are detectable in early stages of lung cancer 
(68%) (27). Early diagnosis of cancer aided by liquid biopsy is 
challenging due to low abundance of CTCs present; therefore, it 
is necessary to develop more sensitive and specific technologies 
that allow more inclusive characterization methodologies that 
will aid early detection of lung cancer.
Current Applications: Culture of CTCs and 
Xenografts
While the exploration of innovative technologies for enhanced 
CTC isolation is always in the forefront of research, ex vivo cultur-
ing and in vivo xenograft models has gradually gained momentum 
in the field. Zhang et al. sorted a subset of breast CTCs to form cell 
lines and tumors in mice (99). This model helped to identify a novel 
gene signature associated with development of brain metastasis. Yu 
et al. successfully cultured breast CTCs followed by in vivo implan-
tation and drug testing (100). Cayrefourcq et al. established and 
characterized a cell line derived from colon CTCs which served as 
a model for studying metastasis and testing treatment agents (101). 
Higher numbers of CTCs in SCLC allow ex vivo culture of these 
cells and formation of CTC-derived xenografts for drug screening 
and mutation detection. In the study by Hodgkinson et al., CTCs 
from SCLC patients were injected directly to mice (42). Samples 
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with CTC count >400/7.5 ml successfully gave rise to tumors in 
mice in 2–4  months. This study demonstrated that CTCs from 
SCLC were tumorigenic and that CTC-derived xenografts termed 
CDXs mirrored the corresponding tumor biopsy specimens. 
CDXs can potentially serve as in vivo drug testing models with 
responses similar to those seen in patients. Next-generation 
sequencing (NGS) revealed similar genomic aberrations in CDXs 
as seen in SCLCs. Our group recently demonstrated capability 
of using a co-culture model to isolate and culture CTCs from 
patients with stages I–III NSCLC (27). A microfluidic co-culture 
model utilizing hydrogel and cancer-associated fibroblasts was 
developed to facilitate CTC culturing. This permitted histological 
characterizations as well as genomic comparison between CTCs 
and matched primary tumors. Culturing of CTCs can overcome a 
critical limitation related to the rarity of these cells. This will allow 
further in vivo and functional studies.
Future Directions
Over the past decade, the advancement of technological 
innovation to isolate CTCs has allowed investigation of their 
clinical utility (102, 103). We now understand that CTCs 
contain heterogeneous populations of both epithelial and 
mesenchymal phenotypes (104). They harbor genetic altera-
tions that correspond to primary tumors and metastatic sites. 
The discordant or unique mutations carried by CTCs that are 
absent in primary tumors reflect heterogeneity in primary 
tumor or small amount of subclonal populations that are 
missed by conventional sequencing methods (105). Together 
with cfDNA, CTCs have been shown as promising surrogates of 
tumor burden and activating mutations for targeted therapies. 
Specifically, CTCs offer opportunities to perform biological 
studies such as phenotypic and histological characterization, 
invasion and migration assays, in  vitro expansion, drug test-
ing, and use as xenografts in animal models. Despite current 
advances in the field, CTC markers still fall short, when it comes 
to factoring inter-tumor and intra-tumor heterogeneity (106). 
We have seen this manifests as discordance in markers between 
primary/metastatic cancers and CTC genotypes or phenotypes. 
Additionally, there is still the problem of contaminating white 
blood cells, despite the emergence of several technologies that 
enable positive selection and negative depletion of leukocytes. 
These factors along with a low yield in earlier stages of lung 
cancer handicap functional studies related to CTCs [e.g., 
ability to detect metastasis initiation properties of lung CTCs 
as demonstrated in other cancers using EPISPOT assay (101, 
107) or invasion capabilities (27, 108)]. In vivo studies of CTCs 
through generating CTC-derived xenografts generally require 
larger numbers of cells (42, 109) which are hard to obtain from 
early stage cancer patients; this can be to some extent overcome 
by increasing blood throughput and sensitivity of isolation 
methods. Biology of metastasis as related to a cascade of events 
has vast implications in drug development. The study of CTCs 
opens up a window for understanding this process. One study 
found that the WNT2 gene was enriched in breast CTCs and 
another study showed that genes involved in ECM were highly 
expressed in pancreatic CTCs (110, 111). These findings suggest 
that these genes and pathways can be targeted therapeutically to 
halt metastasis and likely improve survival. However, this type 
of study has not been done with lung cancer. Understanding 
metastasis initiating capabilities of CTCs from primary lung 
cancer will have a huge impact in providing specific adjuvant 
therapies targeting at these CTCs to reduce metastasis and 
improve survival. The next few years will allow us to further 
study these biological processes in depth and allow meaningful 
translation into the clinic.
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